Back to catalog
Tesamorelin Astral research vial

Tesamorelin

Also known as Tesamorlin · EGRIFTA · TH9507

Stabilized GHRH analog — A 44-amino-acid GHRH analog that stimulates pituitary GH secretion, studied for visceral adipose-tissue reduction in research.

Purity specification: 99%+Lyophilized powder

Available vial sizes

  • 20 mg$109.99In stock

From $109.99In stock

View purchase options

Specifications

CAS number218949-48-5
Molecular formulaC221H366N72O67S
Molecular weight5135.86 g/mol
FormLyophilized powder
Research use only. Not for human or veterinary use, consumption, diagnosis, treatment, or therapeutic purposes.

Documentation

Certificates of Analysis

Batch-specific, third-party lab certificates. Each COA is published here once its lot has been tested — preview the results, then open the full PDF.

No released lot-specific certificates are currently published for this compound. A certificate appears only after its batch clears release and the source PDF is available.

View the compound COA record →

Research context

Sources and references

How is tesamorelin characterized in research?

Tesamorelin is a stabilized growth-hormone-releasing-hormone analog. These references identify its research class and analytical context; they do not constitute directions for use or evidence about an Astral lot.

  1. Analytical review

    Advances in the detection of growth hormone releasing hormone synthetic analogs.

    Memdouh S, Gavrilović I, Ng K, et al. Drug Testing and Analysis (2021).

    Discusses identification and detection of synthetic GHRH analogs, including the analytical identity boundary.

    PMID 34665524 · DOI 10.1002/dta.3183

Editorially curated and source-verified; not independently peer-reviewed by Astral. Last source check: 2026-07-21. How sources are selected.

Read the compound research page →

Related

More to explore

View all